Overview

Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Genotype 4 (GT4) Hepatitis C Virus (HCV) in Egypt

Status:
Completed

Trial end date:
2016-08-01

Target enrollment:

Participant gender:

Summary

This study evaluates the efficacy and safety of ABT-450/r/ABT-267 with RBV in treatment-naive and treatment-experienced HCV GT4 subjects without or with compensated cirrhosis.

Phase:

Phase 3

Details

Lead Sponsor:

AbbVie

Treatments:

Ribavirin
Ritonavir